Dataset Information
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged
Ontology highlight
ABSTRACT:
SUBMITTER: Tesser J
PROVIDER: S-EPMC6701065 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Publications
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
Arthritis research & therapy 20190820 1
<h4>Objective</h4>To evaluate the safety and efficacy of intravenous golimumab + methotrexate (MTX) in patients with active rheumatoid arthritis (RA) aged < 65 years and those ≥ 65 years who were enrolled in the GO-FURTHER study.<h4>Methods</h4>In the phase III, double-blind, randomized, placebo-controlled GO-FURTHER trial, patients with active RA were randomized to intravenous (IV) golimumab 2 mg/kg + MTX or placebo + MTX at weeks 0 and 4, then every 8 weeks thereafter (with crossover to golimu ...[more]